INP20
Peanut Allergy
ClinicalActive
Key Facts
About InnoUp
InnoUp is a private, clinical-stage biotech leveraging its proprietary nanoparticle encapsulation platform to develop novel oral drug delivery solutions. Its pipeline includes two clinical-stage programs: an oral peanut allergy vaccine (INP20) and an oral formulation of paclitaxel for breast cancer (INP12). The company's technology aims to enhance drug bioavailability and enable mucosal immunization, positioning it in the high-growth nanomedicine and drug delivery sectors.
View full company profileOther Peanut Allergy Drugs
| Drug | Company | Phase |
|---|---|---|
| PRT120 | Prota Therapeutics | Phase 3 |
| Food Allergy Program | Hal Allergy | Clinical Development |
| Peanut allergy program | Desentum | Unknown |
| Peanut Oral Immunotherapy | Camallergy | Phase 2 |
| INT301 (implied) | Intrommune Therapeutics | Pre-clinical |
| Ukko-Peanut | Ukko | Preclinical |
| VLP Peanut (VLP-p) | Allergy Therapeutics | Phase II |